3 December 2025 - Top Stories

Asia PGI has launched PathGen, an AI-driven platform designed to enhance pathogen detection and outbreak response across Asia. By integrating genomics, clinical data, climate information, and mosquito habitat data, it aims to provide real-time insights that can help public health officials respond more swiftly to emerging threats. The platform is transitioning from proof-of-concept to a full rollout, with pilots beginning early next year. This development could improve cross-border data sharing and outbreak management, while respecting data sovereignty concerns.

In Australia, CSL Seqirus has opened a new manufacturing facility in Melbourne specialising in cell-based vaccines and antivenoms. The plant, the only one of its kind in the Southern Hemisphere, supports seasonal and pandemic flu vaccine production. With a $1 billion investment, the facility enhances Australia’s vaccine independence and positions the country as a leader in advanced vaccine technology. The plant’s digital and sustainable design aligns with broader efforts to strengthen local health security and supply chains.

• Australia’s government agrees to expand health practitioners' scope of practice, allowing nurses to prescribe and pharmacists to dispense medicines in general practice. This aims to improve efficiency and reduce costs, supported by a $900 million fund for states adopting these reforms.
• Queensland has extended ADHD treatment rights to adults without requiring additional training for GPs. The change is expected to improve access and reduce costs, though some experts caution that proper training remains essential for safe diagnosis and management.
• The Queensland Medical Association has separated from the national AMA to focus on local issues, especially in rural areas. This move could influence advocacy and policy priorities within the state’s healthcare sector.

Meanwhile, Australia’s health system faces calls for better prevention coordination. Fragmented data sharing and lack of a unified long-term strategy hinder progress. Digital health initiatives like Sparked and Healthdirect are advancing, but standardising data sets across primary care remains a priority to improve outcomes.

Innovations in testing and treatment continue, with rapid syphilis tests showing promise for timely diagnosis and intervention. The WHO’s endorsement of long-term GLP-1 therapies for obesity signals a shift towards medical management, prompting health systems to prepare for broader access. Australia’s recent AI strategy highlights opportunities for responsible innovation, with investments in AI safety and applications in diagnostics.

Overall, the sector is witnessing significant shifts in regulation, technology, and workforce strategies. These developments offer opportunities for healthtech companies to support system efficiencies, improve patient care, and navigate evolving policy landscapes.

• Key move: Australia’s expansion of health practitioners’ scope of practice.
• Key move: Launch of PathGen AI platform for disease detection in Asia.
• Key move: New cell-based vaccine facility in Melbourne enhances local supply.
• Key move: Queensland extends ADHD treatment rights to adults.
• Key move: WHO endorses long-term GLP-1 therapies for obesity.
• Key move: Australia’s AI plan promotes responsible innovation and diagnostics.